Skip to main content
Journal cover image

Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial.

Publication ,  Journal Article
Maron, DJ; Newman, JD; Anthopolos, R; Lu, Y; Stevens, S; Boden, WE; Mavromatis, K; Linefsky, J; Nair, RG; Bockeria, O; Gosselin, G; Perna, GP ...
Published in: J Am Coll Cardiol
April 1, 2025

BACKGROUND: Guideline-directed medical therapy (GDMT) with multiple risk factor goals is recommended for patients with chronic coronary disease (CCD), yet achieving all GDMT goals is uncommon. The relative importance of these goals and timing of their attainment on cardiovascular events is uncertain. OBJECTIVES: This study aims to describe the relationship between achieving specific GDMT goals, when they are achieved, and clinical outcomes. METHODS: This was an observational study of participants with CCD in the ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial. The primary outcome was cardiovascular (CV) death or myocardial infarction (MI). GDMT goals were systolic blood pressure (SBP) <130 mm Hg, low-density lipoprotein cholesterol <70 mg/dL, not smoking, and antiplatelet therapy. Frequency of GDMT goals met at baseline and during follow-up is described. Bayesian joint modeling for longitudinal goal status and time-to-event analyses characterized the relative importance of specific GDMT goal attainment and timing with CV death/MI. RESULTS: All 5,179 ISCHEMIA participants were included. Among 4,914 participants with complete data on all 4 GDMT goals at baseline, 386 (9%), 2,073 (42%), 1,843 (38%), and 612 (12%) met 0-1, 2, 3, and 4 GDMT goals, respectively. The 4-year cumulative event rate for CV death/MI was highest for participants who attained no GDMT goals (24.5%; 95% credible interval [CrI]: 13.5%-42.2%) and lowest for those who attained all goals at baseline and remained at goal during follow-up (8.7%; 95% CrI: 6.7%-10.9%). SBP goal attainment was associated with a significant absolute event reduction in CV death/MI (-5.1%; 95% CrI: -11.3% to -1.0%), followed by antiplatelet therapy (-11.2%; 95% CrI: -29.1% to 0.8%), achieving low-density lipoprotein cholesterol <70 mg/dL (-2.0%; 95% CrI: -6.0% to 2.4%), and not smoking (-1.7%; 95% CrI: -9.3% to 4.2%). Ten millimeters of mercury lower SBP during follow-up was associated with 10% relative risk reduction of CV death/MI (RR [relative risk] = 0.90; 95% CrI: 0.82-0.98), after adjusting for other GDMT goals and baseline characteristics. CONCLUSIONS: Among participants with CCD, early attainment and maintenance of GDMT goals, especially SBP, were associated with fewer cardiovascular events. Compared with no GDMT goals at target, having all 4 GDMT goals at target at baseline was associated with an absolute 16% fewer CV deaths and MIs. (ISCHEMIA [International Study of Comparative Health Effectiveness With Medical and Invasive Approaches]; NCT01471522).

Duke Scholars

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

April 1, 2025

Volume

85

Issue

12

Start / End Page

1317 / 1331

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Practice Guidelines as Topic
  • Platelet Aggregation Inhibitors
  • Myocardial Ischemia
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
  • Female
  • Cardiovascular System & Hematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Maron, D. J., Newman, J. D., Anthopolos, R., Lu, Y., Stevens, S., Boden, W. E., … ISCHEMIA Research Group. (2025). Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial. J Am Coll Cardiol, 85(12), 1317–1331. https://doi.org/10.1016/j.jacc.2025.01.028
Maron, David J., Jonathan D. Newman, Rebecca Anthopolos, Ying Lu, Susanna Stevens, William E. Boden, Kreton Mavromatis, et al. “Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial.J Am Coll Cardiol 85, no. 12 (April 1, 2025): 1317–31. https://doi.org/10.1016/j.jacc.2025.01.028.
Maron DJ, Newman JD, Anthopolos R, Lu Y, Stevens S, Boden WE, et al. Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial. J Am Coll Cardiol. 2025 Apr 1;85(12):1317–31.
Maron, David J., et al. “Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial.J Am Coll Cardiol, vol. 85, no. 12, Apr. 2025, pp. 1317–31. Pubmed, doi:10.1016/j.jacc.2025.01.028.
Maron DJ, Newman JD, Anthopolos R, Lu Y, Stevens S, Boden WE, Mavromatis K, Linefsky J, Nair RG, Bockeria O, Gosselin G, Perna GP, Demchenko E, Foo D, Shapiro MD, Champagne MA, Ballantyne C, McCullough P, Lopez-Sendon JL, Rockhold F, Harrell F, Rosenberg Y, Stone GW, Bangalore S, Reynolds HR, Spertus JA, Hochman JS, ISCHEMIA Research Group. Guideline-Directed Medical Therapy and Outcomes in the ISCHEMIA Trial. J Am Coll Cardiol. 2025 Apr 1;85(12):1317–1331.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

April 1, 2025

Volume

85

Issue

12

Start / End Page

1317 / 1331

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Practice Guidelines as Topic
  • Platelet Aggregation Inhibitors
  • Myocardial Ischemia
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
  • Female
  • Cardiovascular System & Hematology